Erika Borlenghi

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Renato Bassan, Orietta Spinelli, Elena Oldani et al. · Blood · 2009 · 429 citations · Full text

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

Uwe Platzbecker, Giuseppe Avvisati, Laura Cicconi et al. · Journal of Clinical Oncology · 2016 · 375 citations · Full text

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Francesco Lo‐Coco, Giuseppe Avvisati, Marco Vignetti et al. · Blood · 2010 · 340 citations

A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy

Alessandra Tucci, Samantha Ferrari, Chiara Bottelli et al. · Cancer · 2009 · 278 citations

Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00

Renato Bassan, Giuseppe Rossi, Enrico Maria Pogliani et al. · Journal of Clinical Oncology · 2010 · 271 citations